PAG
DNLI icon

Private Advisor Group’s Denali Therapeutics DNLI Stock Holding History

Private Advisor Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,925
Closed -$47K – 2020
2020
Q2 		$47K Buy
+1,925
New +$45.3K ﹤0.01% 2131

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Advisor Group's DNLI Position: Q3 2020 in Review

Private Advisor Group sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 1,925 shares — an estimated $47K sold.

Private Advisor Group first reported a position in DNLI in Q2 2020 and held it in 1 quarter. The position peaked at $47K in Q2 2020. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

  • Private Advisor Group reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 1,925 Denali Therapeutics shares in Q3 2020, an estimated $47K.
  • Private Advisor Group first reported a position in Denali Therapeutics in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Denali Therapeutics position peaked at $47K in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.